Advertisements

Berlicort (Hydrocortisone)

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Berlicort (Hydrocortisone)

Quick Facts

Property Description
Active ingredient Hydrocortisone (INN)
Form Tablet, Cream, Injection, Lotion
Pharmacological class Corticosteroid / Glucocorticoid
General purpose Replacement therapy; anti-inflammatory action
Origin Synthetic (mimics endogenous Cortisol)

What Type of Medicine is Berlicort (Hydrocortisone)?

Berlicort contains the active ingredient Hydrocortisone, a powerful medicine classified as a corticosteroid, specifically belonging to the glucocorticoid family of hormones. The substance is chemically identical to Cortisol, the principal steroid hormone naturally produced by the human body in the adrenal glands; hydrocortisone is the designation for cortisol when utilized as a pharmaceutical. This confirms that the drug replaces the body's natural stress hormone. As a pharmaceutical preparation, Hydrocortisone is a synthetic compound manufactured to serve as a substitute for the endogenous hormone. This classification is clinically recognized for its role in maintaining metabolic balance and immune regulation, particularly in managing conditions related to chronic adrenal deficiency.


Composition and Available Preparations of Hydrocortisone

The active ingredient is Hydrocortisone, which may be present in various forms such as Hydrocortisone acetate or Hydrocortisone sodium succinate, depending on the required speed and route of action. This single active ingredient is formulated into a variety of pharmaceutical forms designed for specific administration methods. The Berlicort brand is commonly associated with the oral tablet for systemic treatment, but the substance is also found in solutions for injection and various topical preparations such as creams and lotions.

The availability of these diverse forms ensures the medicine can be delivered precisely to achieve systemic action via the oral route, or targeted local effects via topical applications, ensuring effective delivery for both acute and chronic therapeutic needs.


The General Purpose of Hydrocortisone in Medicine

The general therapeutic purpose of Hydrocortisone is twofold: to provide vital replacement therapy and to act as a powerful anti-inflammatory agent. Hydrocortisone is essential for treating adrenocortical insufficiency, a condition where the adrenal glands fail to produce adequate natural Cortisol needed to maintain life-sustaining functions.

Beyond replacement, the drug's inherent properties allow it to act as an immunosuppressive drug, effectively suppressing the body's inflammatory cascade. Glucocorticoids like hydrocortisone are utilized to manage inflammation across multiple organ systems. This means the medicine is a primary tool for controlling severe swelling and immune overactivity.

Advertisements

What side effects are possible with Berlicort (Hydrocortisone)?

Possible Side Effects and Safety Information

The safety profile of Berlicort (Hydrocortisone) is categorized by both localized reactions and the potential for systemic effects resulting from absorption, particularly with extensive or prolonged use.

Frequency-Classified Adverse Reactions

Adverse reactions most commonly observed at the site of application include burning, itching, irritation, and dryness. Other reactions that may occur are folliculitis, hypertrichosis, acneiform eruptions, and changes in skin appearance such as hypopigmentation, skin atrophy, and striae.

System-Organ-Class (SOC) Safety Concerns

When absorbed systemically, hydrocortisone can affect multiple body systems. Regulatory documents highlight risks across several classes, including:

  • Endocrine Disorders: Suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, and development of Cushingoid state.
  • Infections and Infestations: Increased susceptibility to infections and masking of symptoms.
  • Ophthalmic Disorders: Posterior subcapsular cataracts and glaucoma.
  • Musculoskeletal Disorders: Osteoporosis and muscle weakness.

Serious Adverse Reactions

Serious reactions documented in regulatory sources include HPA axis suppression, which may lead to Acute Adrenal Insufficiency upon abrupt cessation or during stress. Severe infections, gastrointestinal ulceration with possible perforation and hemorrhage, and increased intracranial pressure have also been documented.

Population-Specific Considerations and Restrictions

  • Pediatric Use: Children are at greater risk of systemic toxicity, including HPA axis suppression and potential interference with growth. Close monitoring is noted as necessary for pediatric patients.
  • Duration and Exposure: Prolonged use, application over large surface areas, or use under occlusive dressings significantly augments systemic absorption and increases the risk of side effects. Avoidance of occlusive dressings is a primary safety restriction unless otherwise directed.
  • Contraindication: The medicine is contraindicated in individuals with a history of hypersensitivity to any of its components.
Advertisements

Overdose and Emergency Response

️ Overdose and When to Seek Help

Acute overdose of hydrocortisone is considered rare and is not typically expected to cause life-threatening symptoms in a single instance. The greater concern for overdose presentation stems from prolonged, high-dose exposure, which can lead to a range of complications affecting the body's systems.

Over-exposure may result in symptoms characteristic of Cushing's syndrome, including characteristic changes in body fat distribution, thinning skin, and easy bruising. Furthermore, chronic use of excessive doses can lead to suppression of the natural adrenal hormone production, which may result in a severe withdrawal reaction if the medication is stopped suddenly.

When to Seek Immediate Medical Help:

  • Poison Control: Immediately contact a healthcare professional or a Poison Control Centre if an overdose is suspected, even if the individual appears asymptomatic.
  • Emergent Symptoms: Call emergency services if the person has collapsed, has a seizure, is experiencing severe difficulty breathing, or cannot be awakened.
  • Cardiovascular/Neurological: Seek prompt attention for heart rhythm changes, severe hypertension, or significant and worrying psychological symptoms, such as severe depression or hallucinations.

Overdose management is supportive and symptomatic. Treatment often involves closely monitoring vital signs (pulse, blood pressure) and conducting tests such as an ECG. The therapeutic approach for long-term over-exposure involves gradual adjustment or discontinuation of the corticosteroid under medical supervision.

Advertisements

Therapeutic Uses of Berlicort (Hydrocortisone)

What Berlicort (Hydrocortisone) Treats: Main Uses and Benefits

Hydrocortisone is used to address symptoms related to systemic imbalance and inflammatory states. The medication is commonly used to help with symptoms related to low corticosteroid levels, such as profound fatigue, weakness, and issues related to the body's stress response, in conditions like Adrenocortical Insufficiency. This function provides supportive hormone replacement, which may contribute to improved day-to-day comfort during symptomatic periods.


The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used across domains where additional symptomatic support is needed. It plays a role in managing pronounced symptoms of autoimmune disorders like Lupus and Rheumatoid Arthritis, Inflammatory Bowel Disease (IBD), and acute episodes such as severe allergic reactions and gouty arthritis. Topical applications are relevant for managing symptoms related to inflammatory or irritative states, such as itching and redness in skin conditions like eczema and dermatitis.

Quick Fact: Symptom Management Focus

Therapeutic Focus Symptom Axis
Replacement Therapy Symptoms related to systemic imbalance
Anti-Inflammatory Symptoms related to inflammatory or irritative states
Acute Support Symptoms associated with acute or episodic changes

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Berlicort (Hydrocortisone)

The population eligibility for using Hydrocortisone is strictly governed by regulatory classifications, defining groups who must not use the medicine and those who require conditional use based on pre-existing conditions. Official labeling states that systemic use is contraindicated in individuals with a known hypersensitivity to any component of the medication or those with existing systemic fungal infections.

Use is not recommended or requires extreme caution in several populations. This includes patients with untreated or uncontrolled infections, those exposed to Chickenpox or Measles (if non-immune), and patients with active ocular Herpes Simplex due to specific risks. Caution is also mandatory for patients with liver cirrhosis or renal insufficiency as these conditions may alter the drug's effect.

Population Limitations

Population Group Regulatory Status
Pediatric Requires monitoring; safety not established for some oral forms in those under 18 years.
Pregnancy Permitted only if benefit justifies risk; replacement therapy often maintained.
Lactation Not recommended for mothers on high or prolonged doses.

Eligibility for use in children requires careful risk assessment, particularly due to the potential for HPA axis suppression. For pregnancy and lactation, use is conditional, with specific restrictions advised for mothers on high doses.

Advertisements

What should I know about interactions with other medicines?

Berlicort (hydrocortisone) may interact with numerous other prescription and non-prescription medicines, as well as herbal supplements. Always inform your healthcare provider about all products you are taking to ensure safe co-administration.

Major Drug Interactions

Hydrocortisone is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4) in the liver. Medicines that inhibit this enzyme, such as ketoconazole and itraconazole (antifungals), can significantly increase hydrocortisone levels in the body, raising the risk of side effects. Conversely, drugs that induce CYP3A4, such as phenobarbital, phenytoin, and rifampicin (antibiotic), can decrease hydrocortisone levels, potentially reducing its effectiveness and requiring a dose adjustment.

Interacting Drug Class Example Drugs Potential Effect
CYP3A4 Inducers Rifampicin, Phenytoin Decreased Berlicort effectiveness.
CYP3A4 Inhibitors Ketoconazole, Itraconazole Increased risk of Berlicort side effects.
NSAIDs Aspirin, Ibuprofen, Naproxen Increased risk of gastrointestinal bleeding and ulcers.
Anticoagulants Warfarin Altered blood-thinning effect (may increase or decrease).
Diuretics Furosemide, Thiazides Increased risk of hypokalemia (low potassium levels).
Antidiabetics Insulin, Metformin Decreased blood sugar control (may raise blood glucose).

Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), like ibuprofen or aspirin, is not generally recommended due to a significantly increased risk of serious gastrointestinal issues, including ulcers and bleeding. Patients on anticoagulants (blood thinners) require close monitoring, as hydrocortisone can either enhance or diminish the anticoagulant effect. Additionally, hydrocortisone may raise blood sugar, lessening the effect of antidiabetic medicines, and increase potassium loss when taken with certain diuretics.

Advertisements

Mechanism of Action

Berlicort (hydrocortisone) is a synthetic glucocorticoid that exerts its effects by passively diffusing across cell membranes and binding to the cytoplasmic glucocorticoid receptors (GR). This interaction leads to the translocation of the activated hormone-receptor complex into the cell nucleus, where it binds to specific glucocorticoid response elements (GREs) on the DNA. This binding event modulates gene transcription, leading to the synthesis of various proteins, most notably lipocortin (Annexin A1).

The subsequent inhibition of phospholipase A2 (PLA2) by lipocortin reduces the release of arachidonic acid from membrane phospholipids, which is a key precursor for the synthesis of prostaglandins and leukotrienes. This cascading effect results in a reduction of the inflammatory cascade and suppresses immune responses. The drug mimics the action of endogenous cortisol during stress. Furthermore, it directly modulates the transcription of various pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha).

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Hydrocortisone is administered via several routes, including oral tablets, intravenous (IV) and intramuscular (IM) injection for systemic effects, and topical or rectal preparations for localized conditions. The method and schedule of use are determined by clinical protocols to ensure adherence to therapeutic standards.


Dosing and Administration Structure

Administration Scope Official Instruction
Standard Oral Dosing Daily replacement doses for adults typically range from mathbf15 mg to mathbf25 mg, divided into two or three doses, with the highest dose taken in the morning.
Acute Parenteral Dosing The initial dose for an adrenal crisis is mathbf100 mg via IV bolus, which may be followed by subsequent doses (e.g., mathbf50 mg) repeated every four to six hours.
Timing & Preparation Standard tablets should be taken with or after food; however, modified-release tablets must be taken on awakening, at least 30 minutes before food, and must be swallowed whole.
Population Rules Pediatric replacement dosing is calculated based on Body Surface Area, often mathbf8 to mathbf10 mg/m^2/day. Older adults typically begin treatment at the lower end of the dosing range.
Special Conditions The dose must be temporarily increased (stress dose) during periods of significant physical stress. Following prolonged, high-dose use, the drug should not be stopped abruptly but must be gradually tapered.
Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Berlicort (Hydrocortisone)


Evidence for use in Adrenal Insufficiency

This section will summarize the types of clinical studies, such as randomized trials and observational data, that have investigated the use of Berlicort (Hydrocortisone) to replace the natural hormone cortisol in people with primary or secondary adrenal insufficiency (Addison's disease).

Research has studied Berlicort (Hydrocortisone) as a treatment for the essential hormone cortisol deficiency, evaluating whether outcomes related to the body’s systemic or functional imbalance are addressed. Studies have explored whether the use of this medicine is associated with patterns related to outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in individuals whose bodies do not produce enough cortisol. The general pattern observed in these studies is that Berlicort (Hydrocortisone) was evaluated in research settings as research describes patterns related to addressing this hormone deficiency.

What is still uncertain is the optimal dosing schedule to perfectly mimic the body’s natural cortisol rhythm, even with newer formulations. Follow-up durations were limited in some of the comparison studies between different steroid types, and the overall certainty remains low on whether one specific formulation or timing is definitively superior for long-term health and patient-reported outcomes describing perceived discomfort.


Evidence for use in Congenital Adrenal Hyperplasia (CAH)

This part will outline the research and clinical experience, including studies in children and adults, that supports the use of Berlicort (Hydrocortisone) as a treatment for Congenital Adrenal Hyperplasia (CAH) to manage hormone levels.

Berlicort (Hydrocortisone) was studied for its use in individuals with CAH, a condition marked by functional limitations and systemic imbalance in hormone production. Research highlights changes measured during the study period, primarily related to evaluating the levels of other hormones that can cause issues. Studies explored how symptoms evolved in the observed populations, particularly in growing individuals where the goal is to observe hormone replacement alongside development.

Data are still emerging, especially concerning long-term effects of newer, modified-release formulations that aim to better match the body’s natural hormone release pattern. While Berlicort (Hydrocortisone) was evaluated in children, the ideal glucocorticoid for adults with CAH is still being explored; comparative evidence may be limited between different long-acting and short-acting steroids. Long-term effects are not fully established for all potential outcomes.


Evidence for use in Septic Shock

This section will provide an overview of the clinical trials and systematic reviews that have explored the role of Berlicort (Hydrocortisone) as an additional therapy for managing patients with septic shock who have not responded adequately to standard treatments.

Berlicort (Hydrocortisone) was evaluated in large-scale clinical trials for patients with septic shock, a condition associated with acute or disruptive episodes and monitoring physiological strain or stress. These research efforts explored short-term symptom changes, specifically focusing on outcomes capturing phases of heightened symptom activity, such as how long patients needed life support (vasopressors) to maintain blood pressure.

Research has focused on studies conducted during periods of increased symptom activity. Findings were mixed across different studies when looking at overall survival, with some large trials observed certain patterns while others did not find a significant difference in 90-day mortality. However, data show patterns related to a shorter duration of vasopressor support, a change measured during the study period, findings were observed in the context of certain systemic outcomes in this critical setting.


Long-term Studies and Follow-up

Studies that have observed the use of Berlicort (Hydrocortisone) for chronic conditions over defined time intervals contribute to the broader evidence landscape but often results are noted with long follow-up durations being limited. Research describes patterns related to how long-term use, even at replacement doses, was associated with specific outcomes related to bone health, weight, and blood pressure. These findings describe patterns observed in the studies and findings help contextualize the importance of continued monitoring.

There is limited information for long-term outcomes on the overall durability of response and health in patients, and comparative evidence is lacking for how long-term use of Berlicort (Hydrocortisone) compares against other similar medicines over decades. Long-term effects are not fully established, meaning results apply only to the populations studied, and certainty remains low in predicting individual long-term experiences.


Evidence in Special Populations

This part will outline what specific studies have evaluated the effects of Berlicort (Hydrocortisone) in different groups, such as children, older adults, pregnant or breastfeeding individuals, or those with other coexisting health conditions, and where evidence may be limited.

Berlicort (Hydrocortisone) was evaluated in research contexts involving fluctuating or unstable symptoms across various age groups. For children, research has mainly focused on its use in CAH, and studies monitored outcomes reflecting daily functioning or activity level and physical growth. Data for certain groups, such as very young children, remain insufficient, and for older adults, specific studies are limited.

Evidence suggests that for individuals with certain coexisting conditions, such as diabetes or a history of stomach problems, special consideration was given in study design. Studies focusing on episodes where symptoms become more noticeable due to these coexisting conditions help contextualize how patients reported their experience. The use of Berlicort (Hydrocortisone) in these groups was associated with increased monitoring in research settings.


What is Still Uncertain about Berlicort (Hydrocortisone)

Despite its long history of use, research is ongoing to fully understand all aspects of Berlicort (Hydrocortisone) therapy. Evidence is limited on the true long-term impact on bone density and metabolic health in individuals requiring chronic replacement therapy, particularly in conditions presenting with cycles of stability and flare-ups.

Comparative evidence is lacking to definitively rank Berlicort (Hydrocortisone) against other similar steroid medicines for all long-term outcomes. Furthermore, the results apply only to the populations studied in the research, and research does not determine whether an individual will respond similarly. The study results reflect the specific conditions under which they were conducted.

Key Studies & References Modified-release hydrocortisone for adrenal insufficiency and congenital adrenal hyperplasia: a systematic review

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Berlicort (Hydrocortisone) (FAQ)


Q: How quickly does Berlicort usually start working?

A: Official documentation describes the active ingredient, hydrocortisone, as being readily absorbed from the gastrointestinal tract after it is taken. This rapid absorption is characteristic of its classification as a short-acting medicine. The time it takes for effects to be observed can vary based on the specific condition being treated.


Q: Can you take Berlicort long-term?

A: The prolonged use of this medicine is associated with documented risks, including effects like HPA axis suppression and osteoporosis (weakening of the bones). Because of these risks, official guidelines specify that the medicine should only be used for the exact duration and conditions prescribed.


Q: What does it mean if Berlicort causes 'HPA axis suppression'?

A: HPA axis suppression is listed as a possible endocrine adverse reaction. This term refers to the reduced function of the Hypothalamic-Pituitary-Adrenal axis, which controls how the body responds to stress and regulates metabolism. When this system is suppressed, the body may not be able to produce enough natural cortisol, especially during times of physical stress.


Q: What if I miss a dose of my Berlicort medicine?

A: General patient information leaflets often provide instructions for missed doses, such as advising to take it soon as remembered or skipping it if the next dose is near. Patients should consult their specific medication leaflet or healthcare provider for precise guidance, as this is individualized information.


Q: Can Berlicort weaken the immune system?

A: Yes, corticosteroids like hydrocortisone are known to suppress the immune system. Official documents state that this action may increase the risk of infection or mask the typical signs and symptoms of an existing infection.


Q: What is the average duration of treatment with Berlicort for a short-term issue?

A: The duration of treatment is based on the condition being addressed. Official product information lists that Berlicort is indicated for certain conditions that require short-term administration, but the length of use will vary based on the specific therapeutic need.


Q: Can Berlicort cause mood changes or irritability?

A: Yes, regulatory documentation indicates that mood changes, irritability, anxiety, and depression are among the documented psychological side effects associated with the use of this medicine.


Q: Does Berlicort affect blood sugar levels?

A: Official information confirms that this medicine can cause decreased carbohydrate tolerance and may increase blood sugar levels. Regulatory warnings mention that this may require dose adjustments for those managing diabetes.


Q: Can Berlicort cause thinning of the skin?

A: Yes, dermatologic adverse reactions documented in official sources include the development of thin fragile skin and other changes such as skin atrophy. This is particularly noted with prolonged use of topical forms.


Q: What happens if I use Berlicort cream more often than prescribed?

A: Using topical medicine, such as the cream or lotion, more often or for a longer time than directed can significantly increase systemic absorption. This increased absorption raises the risk of systemic side effects, including the suppression of the HPA axis.


Q: Does Berlicort affect bone density?

A: Yes, long-term use of this medicine is associated with documented musculoskeletal adverse reactions, including the risk of osteoporosis. Osteoporosis involves a reduction in bone density, leading to weaker bones and an increased risk of fracture.


Q: Can Berlicort make you gain weight?

A: Official adverse reaction data shows the medicine may cause fluid retention and sodium retention, which can contribute to weight gain. Additionally, the development of a Cushingoid state, which includes certain types of weight gain, is also a reported endocrine effect.


Q: Is it common to feel tired while taking Berlicort?

A: According to patient guidance based on regulatory data, unusual tiredness or weakness is listed as a possible side effect that may occur during treatment with this medicine.


Q: Are there any common foods or drinks to avoid while using Berlicort?

A: Regulatory-based patient information advises talking to a healthcare provider about consuming grapefruit and grapefruit juice while taking this medicine. This conversation is recommended because grapefruit can sometimes alter how certain medications are processed by the body.


Q: Can Berlicort be used safely by older adults?

A: Official documentation notes that older adults typically begin treatment at the lower end of the dosing range. They may also require closer monitoring, as specified in patient guidelines.


Q: Is Berlicort safe to use during pregnancy?

A: Regulatory information states that use during pregnancy is conditional. It is permitted only if the potential benefit justifies the risk to the fetus. This conditional use is outlined in official information.


Q: Does Berlicort treatment require regular blood tests?

A: Yes, patient information states that a healthcare provider may need to order blood and urine tests to check the patient's progress. These tests help monitor for potential unwanted effects, especially during prolonged use of the medicine.


Q: Is Berlicort addictive?

A: Official regulatory documents indicate that drug abuse and dependence have not been reported in patients treated with this medicine.


Q: Is Berlicort available over the counter?

A: The active ingredient, hydrocortisone, is available in different forms. Specifically, topical forms, such as creams and ointments, are available both as an over-the-counter (OTC) product and with a prescription, depending on the strength.


Q: Is Berlicort indicated for use in joint pain or arthritis?

A: The medicine is officially indicated for use as an adjunctive therapy for a variety of rheumatic disorders. These indications include certain forms of arthritis, such as rheumatoid arthritis and acute gouty arthritis.


Q: Does Berlicort interact with herbal supplements?

A: There is not enough information in regulatory sources to confirm the safety of complementary or herbal remedies when taken with hydrocortisone. Official patient guidelines recommend informing a healthcare provider about all products being taken, including supplements.


Q: Is Berlicort a fast-acting or slow-acting drug?

A: Hydrocortisone is generally classified in clinical practice as a short-acting glucocorticoid. This classification refers to the duration of its biological effect on the body compared to other medicines in the same class.


Q: What is the likelihood of developing a steroid withdrawal syndrome?

A: Regulatory documents warn that the abrupt discontinuation of the medicine after prolonged use can lead to secondary adrenocortical insufficiency. This condition, which is a key part of what is sometimes called 'steroid withdrawal,' is the reason why the drug must be gradually tapered when stopping.


Q: Can Berlicort cause changes in vision?

A: Using the medicine can be associated with documented ophthalmic disorders. These include the potential development of cataracts, glaucoma, and the occurrence of blurred vision or other changes in vision.


Q: Is it possible to be allergic to Berlicort (Hydrocortisone)?

A: Yes, official documentation states that the medicine is contraindicated in patients with a known hypersensitivity (allergic reaction) to hydrocortisone or any of the product's inactive components.


Q: What is the difference between Hydrocortisone cream and ointment?

A: Both cream and ointment are topical forms of the medicine, meaning they are applied to the skin. The difference is primarily in their formulation; they are prepared with different bases or vehicles, which can affect the skin's absorption and texture.


Q: What research has been done on Berlicort's use in autoimmune conditions?

A: Official indications and clinical use include a variety of autoimmune and collagen diseases. For example, the drug is used in conditions like systemic lupus erythematosus and ulcerative colitis, according to regulatory documents.


Q: What is the general goal of treatment when starting Berlicort?

A: The general therapeutic purpose of the medicine is twofold, as described in official documents. It is used to act as a vital replacement therapy for natural cortisol deficiency and to provide a strong anti-inflammatory action.


Q: Is Berlicort a prophylactic (preventive) medicine?

A: The medicine is primarily used for replacement therapy of cortisol that the body is missing and for treating active inflammatory conditions. It is not typically used for general disease prevention in the sense of a prophylactic medicine.


Q: Can Berlicort cause muscle weakness?

A: Yes, muscle weakness and the potential for a condition known as steroid myopathy are documented as musculoskeletal adverse reactions in official product information.

Advertisements

How should Berlicort (Hydrocortisone) be stored and disposed of?

How to Store and Dispose of Berlicort (Hydrocortisone)

The storage and disposal of Hydrocortisone must follow specific regulatory requirements to maintain product stability and safety. The medication must be kept at Controlled Room Temperature, generally defined as 20 C to 25 C (68 F to 77 F), and must be protected from both freezing and excess heat.

Storage Requirements

  • Protection: The product must be stored away from moisture and light.
  • Container: The medicine must be kept in its original container and the container must be tightly closed.
  • Safety: It is mandatory to store the medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired medicine must not be kept. Regulatory instructions direct individuals to consult a healthcare professional or pharmacist for proper disposal methods, often recommending the use of a medication take-back program. The product should not be disposed of in general household trash or flushed into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Berlicort (Hydrocortisone) found in:

A-Z Index: